公司
公司
箭头表示关系方向，可按业务类别筛选。
Mediar is also progressing novel fibro-inflammatory targets as part of a recently announced collaboration with Ono Pharmaceutical.查看来源
Mediar is conducting the Phase 2 WISPer study under a global licensing agreement with Eli Lilly and Company.查看来源
显示第 1 至 2 条，共 2 条
结合来源阅读结论，展开条目查看证据。
Mediar is also progressing novel fibro-inflammatory targets as part of a recently announced collaboration with Ono Pharmaceutical.
PR Newswire news releases · 2026-10-07 19:08
Mediar is also progressing novel fibro-inflammatory targets as part of a recently announced collaboration with Ono Pharmaceutical.查看来源
Mediar is conducting the Phase 2 WISPer study under a global licensing agreement with Eli Lilly and Company.
PR Newswire news releases · 2026-10-07 19:08
Mediar is conducting the Phase 2 WISPer study under a global licensing agreement with Eli Lilly and Company.查看来源
显示第 1 至 2 条，共 2 条
估值数据需要 Pro 或 Research。
升级到 Pro 解锁暂无: 公司信号 · 财务数据 · 披露文件 · 业绩指引
